Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo

IDB Therapeutics Incubator: Request for Proposals 2022

Research Admin Offices:

  • HRS

Funding Type:


Opportunity Type:

  • Grant


IDB anticipate investing up to $ 1,500,000 over a three-year period per project to discover and develop therapeutic drug opportunities for each selected therapeutic target candidate.


  • Health Sciences



Internal Deadline:

September 19, 2022

Sponsor Deadline:

October 3, 2022


The goal of this Request for Proposals (RFP) is to advance drug discovery research to create new therapeutic product opportunities from breakthrough academic research that has identified novel and differentiated potential drug targets for the treatment of Crohn’s disease and/or ulcerative colitis.

In this incubator model, the scientific staff at the Crohn’s & Colitis Foundation, who have extensive drug discovery and development expertise, will take an active role in designing and leading the project(s), in collaboration with the academic applicant and CRO scientists. The R&D work will be mainly performed by the CRO, and if required, some of the research activities can be performed by the academic partner at their facility.


  • Applications from a team with the relevant expertise are required, with one lead Principal Investigator (PI) and at least one Co-PI.
  • PI must be a senior faculty member (Professor, Head of Research, Associate Professor, etc.) with relevant expertise in IBD biology and therapeutic target discovery.
  • Co-PI(s) must be an academic researcher with relevant expertise that is complementary to PI’s expertise, and could include medicinal chemistry, assay development, IBD biology, in vivo pharmacology, etc. and who is at any level of the academic professional track.
  • PI and Co-PIs must be employed by a non-profit research institution. Collaborations of lead PI with for-profit organizations are eligible. International applicants are also eligible to apply and there are no geographical restrictions regarding research site location(s).
  • Applications are strongly encouraged from diverse teams of applicants that include women, underrepresented racial and ethnic groups, individuals with disabilities, and/or individuals from disadvantaged backgrounds.

Application/Nomination Process:

  • Only the primary PI is authorized to submit the application.
  • The proposals will undergo peer review by a multidisciplinary review committee including experts in IBD biology and industry scientists who are experts in drug discovery and development, and it will be evaluated based on the following criteria:
    • In summary, proposed drug targets should meet most if not all the following criteria:
    • Addressing an unmet need in Crohn’s disease and/or ulcerative colitis (required).
    • Linked to the biology of Crohn’s disease and/or ulcerative colitis (required).
    • Novel and differentiated mechanism of action (required).
    • Validated in preclinical proof-of-concept studies (required).
    • Druggable target (required).
    • Available screening assays (desired but not required).
    • Available tool compounds or antibodies (desired but not required).
    • Available biomarkers (desired but not required)
    • Favorable safety profile (desired but not required)


Additional Details


If applying from the Faculty of Health Sciences, unless otherwise indicated, you no longer need to send documents to HRS Intake. Your first point of contact is your assigned Senior Grants Advisor.